Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

601 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. Fenaux P, et al. Among authors: mufti g. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. Blood. 2011. PMID: 21753188 Free article. Clinical Trial.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. Harousseau JL, et al. Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21. Blood. 2009. PMID: 19470696 Free article. Clinical Trial.
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net. Malcovati L, et al. Among authors: mufti g. Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26. Blood. 2013. PMID: 23980065 Free PMC article.
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LB. Fenaux P, et al. Among authors: mufti gj. Ecancermedicalscience. 2008;2:121. doi: 10.3332/ecancer.2008.121. Epub 2008 Dec 10. Ecancermedicalscience. 2008. PMID: 22275991 Free PMC article.
Allogeneic stem cell transplantation in MDS: how? When?
Platzbecker U, Mufti G. Platzbecker U, et al. Among authors: mufti g. Best Pract Res Clin Haematol. 2013 Dec;26(4):421-9. doi: 10.1016/j.beha.2013.09.008. Epub 2013 Oct 1. Best Pract Res Clin Haematol. 2013. PMID: 24507818 Review.
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N. Wanquet A, et al. Among authors: mufti g. Am J Hematol. 2015 Oct;90(10):859-63. doi: 10.1002/ajh.24099. Epub 2015 Jul 14. Am J Hematol. 2015. PMID: 26113240 Free article.
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gilleece MH, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A. Sengsayadeth S, et al. Among authors: mufti g. Blood Adv. 2018 Aug 28;2(16):2127-2135. doi: 10.1182/bloodadvances.2018019976. Blood Adv. 2018. PMID: 30143527 Free PMC article. Clinical Trial.
Thalidomide therapy for low-risk Myelodysplasia.
Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, Mufti G. Bowen D, et al. Among authors: mufti g. Leuk Res. 2005 Feb;29(2):235-6. doi: 10.1016/j.leukres.2004.05.017. Leuk Res. 2005. PMID: 15607375 No abstract available.
Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?
de Witte TM, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N; Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet. de Witte TM, et al. Among authors: mufti g. Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S42-5. doi: 10.1016/j.clml.2014.06.015. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25486954 Review.
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update.
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. Silverman LR, et al. Among authors: mufti gj. Ecancermedicalscience. 2008;2:118. doi: 10.3332/ecancer.2008.118. Epub 2008 Dec 8. Ecancermedicalscience. 2008. PMID: 22275990 Free PMC article.
601 results